The clock is ticking for Iterum after FDA hands down CRL for Pfizer castoff antibiotic
Iterum knew its odds were slim as it awaited an FDA ruling on a key urinary tract infection drug with its bank account running low …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
